These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9829028)

  • 21. [The treatment of the resistant obsessive-compulsive disorder: an update].
    Crespo Facorro B; Gomez-Hernández R
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(1):61-9. PubMed ID: 9133159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
    Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
    J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Pharmacological Treatment of Obsessive-Compulsive Disorder.
    Pittenger C
    Psychiatr Clin North Am; 2023 Mar; 46(1):107-119. PubMed ID: 36740347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-based pharmacotherapy of obsessive-compulsive disorder.
    Fineberg NA; Gale TM
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):107-29. PubMed ID: 15450126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug treatment of obsessive-compulsive disorder.
    Lelliott PT; Monteiro WO
    Drugs; 1986 Jan; 31(1):75-80. PubMed ID: 2866948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].
    Kordon A; Zurowski B; Wahl K; Hohagen F
    Nervenarzt; 2011 Mar; 82(3):319-20, 322-4. PubMed ID: 21340636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.
    Lydiard RB
    Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():33-7. PubMed ID: 7963449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term management of obsessive-compulsive disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():23-9. PubMed ID: 9032001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on the pharmacological treatment of obsessive-compulsive disorder.
    Fontenelle LF; Nascimento AL; Mendlowicz MV; Shavitt RG; Versiani M
    Expert Opin Pharmacother; 2007 Apr; 8(5):563-83. PubMed ID: 17376013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New developments in the treatment of obsessive-compulsive disorder.
    Leonard HL
    J Clin Psychiatry; 1997; 58 Suppl 14():39-45; discussion 46-7. PubMed ID: 9418745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SSRIs in the treatment of obsessive-compulsive disorder.
    Cartwright C; Hollander E
    Depress Anxiety; 1998; 8 Suppl 1():105-13. PubMed ID: 9809222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.